Sidvim LifeSciences Private Limited

Contents Patent applications filed by Nosch Labs Private Limited General information Mapping the RNA therapeutics R&D landscape in 2022 Amgen Extends Collaboration with Syngene International Intellectual Property Suboxone decision by CAFC Patent applications filed by Nosch Labs Private Limited In SIDVIM, we analyse IP (Patent) portfolio of small and medium sized companies. In past we analysed patent portfolios of big generic companies like Sun Pharma, Cipla and Glenmark too. We attempted to analyse their development strategies using combined analysis of Patent portfolio and import/export data. We further estimated development stages of molecules at their respective development centres. This week we looked at patent portfolio of Hyderabad based Nosch Labs Private Limited.  Publication Number Patent family relates to Publication Date WO2016142952A1 Vilazodone and its intermediate process 2016-09-15 WO2016113751A1 Process for preparation of crystalline Linezolid Form III 

  Contents FDA approval in October 2021 General information Bayer wins again in latest Roundup cancer trial Mankind, IPCA, Torrent, Ajanta, Sun Lead Pharma Market Growth in November Intellectual Property Dapagliflozin decision by Delaware Court FDA approval in October 2021 Regulatory Asciminib approved in October 2021 by FDA Asciminib, sold under the brand name Scemblix, is a medication used to treat Philadelphia chromosome-positive chronic myeloid leukaemia.  Chemistry The chemical name of the drug substance is N-[4 (Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-3-yl) pyridine-3-carboxamidehydrogen chloride. Asciminib hydrochloride is a white to slightly yellow powder.  The molecular formula of asciminib hydrochloride is C 20 H 18 ClF 2 N 5 O 3 .HCl, and the relative molecular mass is 486.30 g/mol for the hydrochloride salt and 449.84 g/mol for the free base.  The chemical structure of asciminib hydrochloride is shown below:  Formulation Scemb